UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark one)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30, 2020~~March 31, 2021

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-32929

MOSYS, INC.

(Exact name of registrant as specified in its charter)

Delaware		77-0291941
(State or other jurisdiction		(I.R.S. Employer
of Incorporation or organization)		Identification Number)

2309 Bering Drive

San Jose, California, 95131

(Address of principal executive office and zip code)

(408) 418-7500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

MOSY

The ~~NASDAQ~~Nasdaq Stock Market, LLC

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was ~~3,536,512~~6,134,719 as of ~~August 5, 2020.~~May 7, 2021.

MOSYS, INC.

FORM 10-Q

~~June 30, 2020~~March 31, 2021

TABLE OF CONTENTS

PART I —	FINANCIAL INFORMATION	3

Item 1.	Financial Statements (Unaudited):	3

	Condensed Consolidated Balance Sheets as of ~~June 30, 2020~~March 31, 2021 and December 31, ~~2019~~2020	3

	Condensed Consolidated Statements of Operations and Comprehensive ~~Income (Loss)~~Loss for the three ~~and six~~ months ended ~~June 30,~~March 31, 2021 and 2020 ~~and 2019~~	4

	Condensed Consolidated Statements of Stockholders’ Equity for the three ~~and six~~ months ended ~~June 30,~~March 31, 2021 and 2020 ~~and 2019~~	5

	Condensed Consolidated Statements of Cash Flows for the ~~six~~three months ended ~~June 30,~~March 31, 2021 and 2020 ~~and 2019~~	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1816

Item 4.	Controls and Procedures	2421

PART II —	OTHER INFORMATION	2421

Item 1.	Legal Proceedings	2421

Item 1A.	Risk Factors	2421

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 6.	Exhibits	2623

	Signatures	2724

PART I—~~FINANCI~~ALFINANCIAL INFORMATION

Item 1. Financial Statements

MOSYS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)

	June 30,			December 31,			March 31,			December 31,
	2020			2019			2021			2020
	(unaudited)						(unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	7,375		$	6,053		$	9,529		$	5,889
Short-term investments		—			300			1,610			—
Accounts receivable		601			1,175
Accounts receivable, net								375			701
Inventories		1,016			968			862			599
Prepaid expenses and other		311			472			534			668
Total current assets		9,303			8,968			12,910			7,857
Property and equipment, net		127			197			105			121
Right-of-use lease asset, net		63			156			254			303
Other		18			78			18			17
Total assets	$	9,511		$	9,399		$	13,287		$	8,298
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	48		$	218		$	81		$	76
Deferred revenue		—			166			15			15
Short-term lease liability		66			166			201			201
PPP note payable, current		195			—			434			244
Accrued expenses and other		1,302			1,155			1,291			1,300
Total current liabilities		1,611			1,705			2,022			1,836
Convertible notes payable		2,970			2,858			—			3,092
PPP note payable		384			—			145			335
Long-term lease liability								57			103
Total liabilities		4,965			4,563			2,224			5,366
Commitments and contingencies (Note 4)
Stockholders’ equity
Preferred stock, $0.01 par value; 20,000 shares authorized; none issued and outstanding		—			—			—			—
Common stock, $0.001 par value; 120,000 shares authorized; 3,534 shares and 2,179 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively		3			2
Common stock, $0.001 par value; 120,000 shares authorized; 6,134 shares and 3,554 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively								6			3
Additional paid-in capital		245,426			243,281			255,046			245,548
Accumulated other comprehensive loss								(1	)		—
Accumulated deficit		(240,883	)		(238,447	)		(243,988	)		(242,619	)
Total stockholders’ equity		4,546			4,836			11,063			2,932
Total liabilities and stockholders’ equity	$	9,511		$	9,399		$	13,287		$	8,298

The accompanying notes are an integral part of these condensed consolidated financial statements.

MOSYS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE ~~INCOME (LOSS)~~LOSS

(Unaudited)

(In thousands, except per share data)

	Three Months Ended						Six Months Ended						Three Months Ended
	June 30,						June 30,						March 31,
	2020			2019			2020			2019			2021			2020
Net revenue
Product	$	1,679		$	2,810		$	2,747		$	6,196		$	1,178		$	1,068
Royalty and other		289			256			481			390			160			192
Total net revenue		1,968			3,066			3,228			6,586			1,338			1,260
Cost of net revenue		604			1,228			1,134			2,582			495			530
Gross profit		1,364			1,838			2,094			4,004			843			730
Operating expenses
Research and development		985			981			1,946			2,134			1,159			961
Selling, general and administrative		964			932			2,099			1,904			1,071			1,135
Total operating expenses		1,949			1,913			4,045			4,038			2,230			2,096
Loss from operations		(585	)		(75	)		(1,951	)		(34	)		(1,387	)		(1,366	)
Interest expense		(56	)		(56	)		(111	)		(110	)		(30	)		(55	)
Other income, net		2			28			18			51			48			16
Net loss		(639	)		(103	)		(2,044	)		(93	)	$	(1,369	)	$	(1,405	)

Deemed dividend for warrant exercise price adjustment		(392	)		—			(392	)		—
Net loss attributable to common stockholders	$	(1,031	)	$	(103	)	$	(2,436	)	$	(93	)
Other comprehensive loss, net of tax:
Net unrealized loss on available-for-sale securities														(1	)		—
Comprehensive loss													$	(1,370	)	$	(1,405	)

Net loss per share attributable to common stockholders
Net loss per share
Basic and diluted	$	(0.32	)	$	(0.05	)	$	(0.88	)	$	(0.04	)	$	(0.28	)	$	(0.61	)

Shares used in computing net loss per share
Basic and diluted		3,265			2,159			2,780			2,156			4,862			2,295



Other comprehensive income, net of tax:
Net loss	$	(639	)	$	(103	)	$	(2,044	)	$	(93	)
Net unrealized gains on available-for-sale securities		—			1			—			1
Comprehensive loss	$	(639	)	$	(102	)	$	(2,044	)	$	(92	)

Note: Share and per share amounts for the three and six months ended June 30, 2019 have been adjusted to reflect the impact of a 1-for-20 reverse stock split effected in August 2019, as discussed in Note 1.

The accompanying notes are an integral part of these condensed consolidated financial statements.

MOSYS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands)

																							Accumulated
																				Additional			Other
																Common Stock				Paid-In			Comprehensive			Accumulated
																Shares		Amount		Capital			Loss			Deficit			Total
Balance as of December 31, 2020																	3,554	$	3	$	245,548			—		$	(242,619	)	$	2,932
Issuance of common stock under stock plan, net																	16		—		(2	)		—			—			(2	)
Exercise of warrants																	1,033		1		2,477			—			—			2,478
Issuance of common stock for payment of accrued interest																	43		—		140			—			—			140
Sale of common stock, net of placement costs																	1,488		2		6,815			—			—			6,817
Stock-based compensation																	—		—		68			—			—			68
Unrealized loss on available-for-sale investments																	—		—		—			(1	)		—			(1	)
Net loss																	—		—		—			—			(1,369	)		(1,369	)
Balance as of March 31, 2021																	6,134	$	6	$	255,046		$	(1	)	$	(243,988	)	$	11,063


								Accumulated															Accumulated
					Additional			Other												Additional			Other
	Common Stock				Paid-In			Comprehensive		Accumulated						Common Stock				Paid-In			Comprehensive			Accumulated
	Shares		Amount		Capital			Income		Deficit			Total			Shares		Amount		Capital			Loss			Deficit			Total
Balance as of December 31, 2019		2,179	$	2	$	243,281			—	$	(238,447	)	$	4,836			2,179	$	2	$	243,281			—		$	(238,447	)	$	4,836
Issuance of common stock for release of awards		20		—		(1	)		—		—			(1	)		20		—		(1	)		—			—			(1	)
Exercise of pre-funded warrants		116		—		2			—		—			2			116		—		2			—			—			2
Stock-based compensation		—		—		68			—		—			68			—		—		68			—			—			68
Net loss		—		—		—			—		(1,405	)		(1,405	)		—		—		—			—			(1,405	)		(1,405	)
Balance as of March 31, 2020		2,315		2		243,350			—		(239,852	)		3,500			2,315	$	2	$	243,350		$	—		$	(239,852	)	$	3,500
Issuance of common stock for release of awards		1		—		—			—		—			—
Sale of common stock, net of financing costs		1,218		1		1,618			—		—			1,619
Deemed dividend for warrant exercise price adjustment		—		—		392			—		(392	)		—
Stock-based compensation		—		—		66			—		—			66
Net loss		—		—		—			—		(639	)		(639	)
Balance as of June 30, 2020		3,534	$	3	$	245,426		$	—	$	(240,883	)	$	4,546


								Accumulated
					Additional			Other
	Common Stock				Paid-In			Comprehensive		Accumulated
	Shares		Amount		Capital			Income		Deficit			Total
Balance as of December 31, 2018		2,148	$	2	$	243,022			—	$	(235,867	)	$	7,157
Issuance of common stock for release of awards		9		—		(1	)		—		—			(1	)
Stock-based compensation		—		—		(4	)		—		—			(4	)
Net income		—		—		—			—		10			10
Balance as of March 31, 2019		2,157		2		243,017			—		(235,857	)		7,162
Issuance of common stock for release of awards		5		—		—			—		—			—
Stock-based compensation		—		—		119			—		—			119
Unrealized gain on available-for-sale investments		—		—		—			1		—			1
Net loss		—		—		—			—		(103	)		(103	)
Balance as of June 30, 2019		2,162	$	2	$	243,136		$	1	$	(235,960	)	$	7,179

The accompanying notes are an integral part of these condensed consolidated financial statements.

MOSYS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Six Months Ended						Three Months Ended
	June 30,						March 31,
	2020			2019			2021			2020
Cash flows from operating activities:
Net loss	$	(2,044	)	$	(93	)	$	(1,369	)	$	(1,405	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		82			111			18			41
Stock-based compensation		134			115			68			68
Accrued interest		112			110			30			55
Other		(7	)		(7	)
Amortization of lease right-of-use asset								49			47
Change in operating lease liability								(46	)		(50	)
Gain on settlement of convertible notes payable and accrued interest, net								(48	)		—
Changes in assets and liabilities:
Accounts receivable		574			267			325			636
Inventories		(48	)		547			(263	)		(137	)
Prepaid expenses and other assets		221			(21	)		134			(35	)
Accounts payable		(170	)		(148	)		5			(111	)
Deferred revenue and other liabilities		(19	)		(490	)		84			183
Net cash provided by (used in) operating activities		(1,165	)		391
Net cash used in operating activities								(1,013	)		(708	)
Cash flows from investing activities:
Purchases of property and equipment		(12	)		(55	)		(2	)		(6	)
Proceeds from maturities of short-term investments		300			500			—			300
Purchases of short-term investments		—			(1,567	)		(1,611	)		—
Net cash provided by (used in) investing activities		288			(1,122	)		(1,613	)		294
Cash flows from financing activities:
Proceeds from PPP note		579			—
Proceeds from sale of common stock, net of financing costs		1,619			—
Net proceeds from exercise of pre-funded warrants		2			—
Proceeds from sale of common stock, net								6,817			—
Proceeds from exercise of common stock warrants								2,478			2
Repayment of convertible notes payable								(3,027	)		—
Taxes paid to net share settle equity awards		(1	)		(1	)		(2	)		(1	)
Net cash provided by (used in) financing activities		2,199			(1	)
Net cash provided by financing activities								6,266			1
Net increase (decrease) in cash and cash equivalents		1,322			(732	)		3,640			(413	)
Cash and cash equivalents at beginning of period		6,053			7,104			5,889			6,053
Cash and cash equivalents at end of period	$	7,375		$	6,372		$	9,529		$	5,640
Supplemental disclosure:
Issuance of convertible note in settlement of accrued interest	$	112		$	78
Fair value of warrant exercise price adjustment considered as deemed dividend	$	392		$	—
Issuance of convertible notes in settlement of accrued interest							$	—		$	112
Settlement of accrued interest through issuance of common shares							$	123		$	—

The accompanying notes are an integral part of these condensed consolidated financial statements.

MOSYS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. The Company and Summary of Significant Accounting Policies

MoSys, Inc. (the Company) was incorporated in California in ~~September~~ 1991 and reincorporated in ~~September~~ 2000 in Delaware. The Company provides both integrated circuits (ICs) and intellectual property (IP) solutions that enable fast, intelligent data access and decision making for a wide range of markets. The Company’s ~~strategy~~primary product line is marketed under the Accelerator Engine name and ~~primary business objective is to be an IP-rich fabless semiconductor company focused on~~includes the ~~development~~Bandwidth Engine IC products, which integrate the Company’s proprietary, 1T-SRAM high-density embedded memory and ~~sale~~a highly-efficient serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance. In 2020, the Company began offering for license the first of ~~integrated circuit (IC)~~its Virtual Accelerator Engine products which consist of software, firmware and related IP. This new product line will include multiple function accelerator platform products, which target specific application functions and will use a common software ~~and firmware products.~~interface to allow performance scalability over multiple hardware environments.

The accompanying condensed consolidated financial statements of the Company have been prepared without audit.

The condensed consolidated balance sheet as of December 31, ~~2019~~2020 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three ~~and six~~ months ended ~~June 30, 2020~~March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2020~~2021 or for any other future period.

Basis of Presentation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year.

Risks and Uncertainties

The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.

COVID-19

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.

~~Reverse Stock Split~~

On August 27, 2019, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of the Company’s shares of common stock. Such amendment and ratio were previously approved by the Company’s stockholders and board of directors, respectively.

As a result of the reverse stock split, which was effective August 28, 2019, every 20 shares of the Company’s pre-reverse split outstanding common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split; stockholders who would otherwise hold a fractional share of the Company’s common stock received cash in an amount equal to the product obtained by multiplying (i) the closing sale price of the common stock on the effective date of the reverse stock split as reported on The Nasdaq Stock Market, by (ii) the number of shares of the common stock held by the stockholder that would otherwise have been exchanged for the fractional share interest. All stock options and restricted stock units outstanding and common stock reserved for issuance under the Company’s equity incentive plans and warrants outstanding and the conversion price of the convertible notes outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by 20 and, as applicable, multiplying the exercise price by 20, as a result of the reverse stock split.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at

the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.

Cash Equivalents and Investments

The Company ~~invests~~has invested its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in the value judged to be other than temporary are included in the other income, net line item in the condensed consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific identification method. ~~As of June 30, 2020 the Company did not have any short-term investments.~~

Fair Value Measurements

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date.

Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale securities, which consist primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities.

Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.

Allowance for Doubtful Accounts

The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. ~~There was no~~The allowance for doubtful accounts ~~receivable~~was $41,000 at ~~either June 30, 2020 or~~March 31, 2021 and December 31, ~~2019.~~2020.

Inventories

The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and

quantification of slow moving inventory items. The Company recorded ~~a $0.1 million write down~~no material write-downs of inventory during the ~~six~~three months ended ~~June 30, 2020~~March 31, 2021 and recorded ~~no material inventory~~ write-downs ~~during~~of $0.1 million for the ~~six months~~year ended ~~June 30, 2019.~~December 31, 2020.

Revenue Recognition

The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

IC products

Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied.

The majority of the ~~Company's~~Company’s contracts have a single performance obligation to transfer products. Accordingly, the Company recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically less than 60 days.

Royalty and other

The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter.

Contract liabilities – deferred revenue

The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue.

During the ~~six~~three months ended ~~June 30, 2020,~~March 31, 2021, the Company recognized no revenue ~~of $0.2 million~~ that had been included in deferred revenue as of December 31, ~~2019.~~2020.

See Note 5 for disaggregation of revenue by geography.

Cost of Net Revenue

Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products.

Warrants

As of ~~June 30, 2020,~~March 31, 2021, the Company had the following warrants outstanding ~~to purchase its common stock~~ (share amounts in thousands):


Warrant type	Number of Shares		Exercise Price		Expiration
Warrant Type						Number of Shares		Exercise Price		Expiration
Common stock		33	$	47.00	January 2023		33	$	47.00	January 2023
Common stock		1,846	$	2.40	October 2023		813	$	2.40	October 2023

Per Share Amounts

Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share gives effect to all potentially dilutive shares of common ~~shares~~stock outstanding during the period. Potentially dilutive shares of common ~~shares~~stock consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with ~~the outstanding~~ convertible notes.

The following table sets forth securities outstanding ~~which~~that were excluded from the computation of diluted net ~~income (loss)~~loss per share as their inclusion would be anti-dilutive (in thousands):



	June 30,				March 31,
	2020		2019		2021		2020
Options outstanding to purchase common stock		161		82		159		161
Unvested restricted common stock units		81		107		58		82
Convertible notes		262		240		-		254
Warrants		1,879		1,994		846		1,879
Total		2,383		2,423		1,063		2,376

Note 2: Fair Value of Financial Instruments

The estimated fair values of financial instruments outstanding were (in thousands):

June 30, 2020

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

Cash and cash equivalents

$
7,375

$
—

$
—

$
7,375

	March 31, 2021
			Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Value
Cash and cash equivalents	$	9,529	$	—	$	—		$	9,529
Short-term investments		1,611		—		(1	)		1,610
	$	11,140	$	—	$	(1	)	$	11,139

December 31, 2019

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

Cash and cash equivalents

$
6,053

$
—

$
—

$
6,053

Short-term investments

300

—

—

300

$
6,353

$
—

$
—

$
6,353

	December 31, 2020
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
Cash and cash equivalents	$	5,889	$	—	$	—	$	5,889

The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):

June 30, 2020

Fair Value

Level 1

Level 2

Level 3

Money market funds

$
3,892

$
3,892

$
—

$
—

	March 31, 2021
	Fair Value		Level 1		Level 2		Level 3
Money market funds	$	7,276	$	7,276	$	—	$	—
Corporate notes and commercial paper	$	1,610	$	—	$	1,610	$	—

December 31, 2019

Fair Value

Level 1

Level 2

Level 3

Money market funds

$
4,574

$
4,574

$
—

$
—

Corporate notes and commercial paper

$
300

$
—

$
300

$
—

	December 31, 2020
	Fair Value		Level 1		Level 2		Level 3
Money market funds	$	3,893	$	3,893	$	—	$	—

There were no transfers in or out of Level 1 and Level 2 securities during the ~~six~~three months ended ~~June 30, 2020~~March 31, 2021 or ~~2019.~~2020.

Note 3. Balance Sheet Detail

	June 30,		December 31,		March 31,		December 31,
	2020		2019		2021		2020
	(in thousands)				(in thousands)
Inventories:
Work-in-process	$	567	$	746	$	654	$	414
Finished goods		449		222		208		185
	$	1,016	$	968	$	862	$	599

Note 4. Commitments and Contingencies

Indemnification

In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s condensed consolidated financial statements for the three ~~and six~~ months ended ~~June 30,~~March 31, 2021 or 2020 ~~or 2019~~ related to these indemnifications.

The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any material payments related to these indemnification agreements.

Legal Matters

The Company is not a party to any legal proceeding that the Company believes is likely to have a material adverse effect on its condensed consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts.

Note 5. Business Segments, Concentration of Credit Risk and Significant Customers

The Company operates in one business segment and uses one measurement of profitability for its business. Net revenue is attributed to the United States and to all foreign countries based on the geographical location of the customer.

The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands):

	Three Months Ended				Six Months Ended				Three Months Ended
	June 30,				June 30,				March 31,
	2020		2019		2020		2019		2021		2020
North America	$	1,807	$	2,587	$	2,618	$	5,074	$	948	$	812
Japan		14		346		250		1,252		274		237
Taiwan		108		54		247		128		79		138
Rest of world		39		79		113		132		37		73
Total net revenue	$	1,968	$	3,066	$	3,228	$	6,586	$	1,338	$	1,260

Customers who accounted for at least 10% of total net revenue were:

	Three Months Ended		Six Months Ended		Three Months Ended
	June 30,		June 30,		March 31,
	2020	2019	2020	2019	2021	2020
Customer A	44%	*%	32%	*%	38%	26%
Customer B	29%	12%	28%	13%	20%	19%
Customer C	*%	29%	*%	26%	18%	14%
Customer D	*%	27%	*%	21%	*%	12%
Customer E					*%	11%

*	Represents less than 10%

~~Four~~Three customers accounted for ~~99%~~74% of accounts receivable as of ~~June 30, 2020. Four~~March 31, 2021. Three customers accounted for ~~85%~~86% of accounts receivable as of December 31, ~~2019.~~2020.

Note 6. Income Tax Provision

The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized.

The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. All tax returns from 2014 to 2019 may be subject to examination by the Internal Revenue Service, California and other states. Returns filed in foreign jurisdictions may be subject to examination for the years 2010 to 2019. As of ~~June 30, 2020,~~March 31, 2021, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted on March 27, 2020 in the United States. The CARES Act includes several significant provisions for corporations, including the usage of net operating losses and payroll benefits. As a result of the CARES Act, the Company was able to file for and collect a $0.1 million federal tax receivable for a prior-period alternative minimum tax credit.

Note 7. Stock-Based Compensation

Common Stock Equity Plans

In 2010, the Company adopted the 2010 Equity Incentive Plan and later amended it in 2014, 2017 and 2018 (the Amended 2010 Plan). The ~~expense relating~~Amended 2010 Plan was terminated in August 2019 and remains in effect as to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The unamortized compensation cost, as of June 30, 2020, was $0.2 million related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 1.9 years. The expense related to restricted stock units (RSUs) is recognized over a three-to-five year vesting period and is based on the fair value of the underlying stock on the dates of grant. The unamortized compensation cost, as of June 30, 2020, was $0.2 million related to RSUs and is expected to be recognized as expense over a weighted-average period of approximately 1.6 years.

~~For the three and six months ended June 30, 2020 and 2019, there were no excess tax benefits associated with the exercise of stock options due~~outstanding equity awards granted prior to the ~~Company’s historical loss positions.~~

~~Valuation Assumptions~~

~~There~~date of expiration. As of March 31, 2021, no new awards may be made under the Amended 2010 Plan, and equity awards for approximately 57,858 shares were no awards granted during the six months ended June 30, 2020. The fair value of the Company’s stock options granted during the six months ended June 30, 2019 was estimated on the grant dates using the Black-Scholes valuation option-pricing model with the following assumptions:

	~~Six Months Ended~~
	~~June 30, 2019~~
~~Risk-free interest rate~~		~~2.5~~	%
~~Volatility~~		~~128.4~~	%
~~Expected life (years)~~	~~3.0 - 5.0~~
~~Dividend yield~~		—	%

The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. The expected volatility was based on the historical volatility of the Company’s stock price over the expected term of the options. The expected term of options granted was derived from historical data based on employee exercises and post‑vesting employment termination behavior. A dividend yield of zero is applied because the Company has never paid dividends and has no intention to pay dividends in the near future. The Company accounts for forfeitures as they occur.

~~Common Stock Options and Restricted Stock~~outstanding.

In August 2019, the Company’s stockholders approved the 2019 Stock Incentive Plan (the 2019 Plan), and ~~as a result,~~it replaced the Amended ~~and Restated~~ 2010 Equity Incentive Plan (the 2010 Plan) was terminated. No future grants of awards will be made under the 2010 Plan, although it will continue to govern prior awards granted thereunder, until all such awards granted have been exercised, forfeited, canceled, expired or otherwise terminated in accordance with their terms.Plan. The 2019 Plan authorizes the board of directors or the compensation committee of the board of directors to grant a broad range of awards including stock options, stock appreciation rights, restricted stock, performance-based awards, and restricted stock units. Under the 2019 Plan, 182,500 shares have been reserved for issuance. The 2019 Plan provides for annual option grants or other awards to the Company’s non-employee directors to acquire up to 2,000 shares and for a one-time grant of an option or other award to a non-employee director to acquire up to 6,000 shares upon his or her initial appointment or election to the board of directors.

Under the 2019 Plan, the term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, awards under the 2019 Plan will vest over a three to four-year period, and options will have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company.

The Amended 2010 Plan and the 2019 Plan are referred to collectively as the “Plans.”

The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The unamortized compensation cost, as of March 31, 2021, was $0.1 million related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 1.25 years. The expense related to restricted stock units (RSUs) is generally recognized over a three-year

vesting period and is based on the fair value of the underlying stock on the dates of grant. The unamortized compensation cost, as of March 31, 2021, was $0.2 million related to RSUs and is expected to be recognized as expense over a weighted-average period of approximately 0.5 years.

For the three months ended March 31, 2021 and 2020, there were no excess tax benefits associated with the exercise of stock options due to the Company’s historical loss positions.

Valuation Assumptions

There were no stock options granted during the three months ended March 31, 2021 and 2020.

Common Stock Options and Restricted Stock

The term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, options granted under the 2019 Plan will vest over a three to four-year period and have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company.

~~A summary of option~~The following table summarizes the activity in the shares available for grant under the ~~2010 Plan and~~Plans during the ~~2019 Plan is presented below~~three months ended March 31, 2021 (in thousands, except exercise price):

Options outstanding

Weighted

Shares

Average

Available

Number of

Exercise

for Grant

Shares

Prices

Balance as of January 1, 2020

88

161

$
10.85

Activity

—

—

$
—

Balance as of June 30, 2020

88

161

$
10.85

				Options outstanding
						Weighted
	Shares					Average
	Available			Number of		Exercise
	for Grant			Shares		Prices
Balance as of January 1, 2021		81			159	$	10.82
RSUs granted		(10	)		—		—
Balance as of March 31, 2021		71			159	$	10.82

A summary of RSU activity under the ~~Plan~~Plans is presented below (in thousands, except for fair value):

Weighted

Average

Number of

Grant-Date

Shares

Fair Value

Non-vested shares as of January 1, 2020

103

$
3.75

Vested

(21
)

$
3.80

Non-vested shares as of March 31, 2020

82

$
3.74

Cancelled

(1
)

$
4.55

Non-vested shares as of June 30, 2020

81

$
3.73

				Weighted
				Average
	Number of			Grant-Date
	Shares			Fair Value
Non-vested shares as of January 1, 2021		65		$	3.48
Granted		10		$	3.25
Vested		(17	)	$	3.78
Non-vested shares as of March 31, 2021		58		$	3.35

The fair value of the RSU granted during the three months ended March 31, 2021 was $32,500.

The total intrinsic value of the RSUs outstanding as of ~~June 30, 2020~~March 31, 2021 was ~~$0.1~~$0.2 million.

The following table summarizes significant ranges of outstanding and exercisable options as of ~~June 30, 2020~~March 31, 2021 (in thousands, except contractual life and exercise price):

	Options Outstanding						Options Exercisable						Options Outstanding						Options Exercisable
			Weighted												Weighted
			Average												Average
			Remaining		Weighted				Weighted						Remaining		Weighted				Weighted
			Contractual		Average				Average		Aggregate				Contractual		Average				Average		Aggregate
	Number		Life		Exercise		Number		Exercise		Intrinsic		Number		Life		Exercise		Number		Exercise		Intrinsic
Range of Exercise Price	Outstanding		(in Years)		Price		Exercisable		Price		value		Outstanding		(in Years)		Price		Exercisable		Price		value
$1.57 - $14.99		144		8.76	$	2.64		43	$	3.10	$	28		143		8.01	$	2.62		79	$	2.88	$	185
$15.00 - $25.59		8		3.24	$	15.00		5	$	15.00	$	—		8		2.49	$	15.00		8	$	15.00	$	—
$25.60 - $143.99		3		3.86	$	41.88		2	$	47.46	$	—		2		3.11	$	41.81		2	$	41.81	$	—
$144.00 - $409.99		5		6.15	$	144.00		5	$	144.00	$	—		5		5.40	$	144.00		5	$	144.00	$	—
$410.00 - $924.00		1		4.69	$	430.64		1	$	430.64	$	—		1		3.94	$	430.64		1	$	430.64	$	—
$1.57 - $924.00		161		8.29	$	10.85		56	$	25.97	$	28		159		8.04	$	10.82		95	$	16.55	$	185

There were no stock options exercised during the ~~six~~three months ended ~~June 30, 2020~~March 31, 2021 or ~~2019.~~2020.

Note 8: Stockholders’ Equity

~~On April 21, 2020,~~In February 2021, the Company completed a registered direct offering of securities under an effective registration statement filed with the SEC pursuant to the Securities Act of 1933, as amended. In the offering, the Company sold ~~1,218,000~~1,487,601 shares of common stock at a price of ~~$1.56~~$5.00 per share to institutional investors. Net proceeds of the offering, after placement agent and other fees and expenses paid by the Company, were approximately ~~$1.6~~$6.8 million. As

During the three months ended March 31, 2021, the Company received a ~~result~~total of ~~the offering,~~$2,478,461 of proceeds from the exercise ~~price~~ of ~~the 1,845,540 outstanding~~1,032,692 warrants to purchase shares of common stock ~~purchase warrants that were issued in October 2018 was reduced from $6.00 per share to~~at a price of $2.40 per share. The Company accounted for the warrant exercise price adjustment in accordance with Accounting Standards Codification Topic 260 and determined that the change in the exercise price results in a deemed dividend of $392,000 that increased the net loss attributable to common stockholders at June 30, 2020.

Note 9. Notes Payable

Convertible Notes

In March 2016, the Company entered into a 10% Senior Secured Convertible Note Purchase Agreement (the Purchase Agreement) with the purchasers of $8,000,000 principal amount of 10% Senior Secured Convertible Notes due August 15, 2018 (the Notes), at par, in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Pursuant to amendments to the Notes and related documents in February and October 2018, the interest rate was reduced to 8%, the maturity date of the Notes was extended to August 15, 2023, and the optional conversion price was reduced from $170.00 of Note principal per share of common stock to $11.434 of Note principal per share of common stock. The conversion price is subject to adjustment upon certain events, such as stock splits, reverse stock splits, stock dividends and similar kinds of transactions, as set forth in the Purchase Agreement. Pursuant to a security agreement, the Notes are secured by a security interest in all of the assets of the Company.

Accrued interest is payable semi-annually in cash or in kind through the issuance of identical new Notes, or with a combination of the two, at the Company’s option. The Notes are noncallable and nonredeemable by the Company. The Notes are redeemable at the election of the holders if the Company experiences a fundamental change (as defined in the Notes), which generally would occur in the event (i) any person acquires beneficial ownership of shares of common stock of the Company entitling such person to exercise at least 40% of the total voting power of all of the shares of capital stock of the Company entitled to vote generally in elections of directors, (ii) an acquisition of the Company by another person through a merger or consolidation, or the sale, transfer or lease of all or substantially all of the Company’s assets, or (iii) the Company’s current directors cease to constitute a majority of the board of directors of the Company within a 12-month period, disregarding for this purpose any director who voluntarily resigns as a director or dies while serving as a director. Effective February 2018, pursuant to one amendment to the Notes, the redemption price was reduced from 120% to 100% of the principal amount of the Note to be repurchased plus accrued and unpaid interest as of the redemption date.

No Note holder shall be entitled to convert such holder’s Note if effective upon the applicable conversion date (i) the holder would have beneficial ownership of more than 19.9% of the voting capital stock of the Company as determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, (with exceptions specified in the Purchase Agreement), or (ii) if the shares are being acquired or held with a purpose or effect of changing or influencing control of the Company, or in connection with or as a participant in any transaction having that purpose or effect, as determined in the sole discretion of the board of directors of the Company. There is no required sinking fund for the Notes. The Notes have not been registered for resale, and the holder(s) do not have registration rights.

The Notes restrict the ability of the Company to incur any indebtedness for borrowed money, unless such indebtedness by its terms is expressly subordinated to the Notes in right of payment and to the security interest of the Note holder(s) in respect to the priority and enforcement of any security interest in property of the Company securing such new debt; provided that the Note holder(s) security interest and cash payment rights under the Notes shall be subordinate to a maximum of $5,000,000 of indebtedness for a secured accounts receivable line of credit facility provided to the Company by a bank or institutional lender; and, provided further, that in no event may the amount of indebtedness to which the security interest of the Note holder(s) is subordinated exceed the outstanding balance of accounts receivable less than 90 days old for which the Company has not recorded an allowance for doubtful accounts pledged under such credit facility.

The Notes define an event of default generally as any failure by the Company to pay an amount owed under the Notes when due (subject to cure periods), a default with respect to other indebtedness of the Company resulting in acceleration of such indebtedness, the commencement of bankruptcy or insolvency proceedings, or the cessation of business. If an event of default occurs under the Notes, the holder(s) of a majority-in-interest of the outstanding principal amount of the Notes may declare the outstanding principal amount thereof to be immediately due and payable and pursue all available remedies, including taking possession of the assets of the Company and selling them to pay the amount of debt then due, plus expenses, in accordance with applicable laws and procedures.

In accordance with the October 2018 amendment to the Notes, the Company used $7.4 million of the proceeds from a public offering of securities effected in October 2018 to repay a portion of the Notes. Semi-annual interest payments have been made in each of February 2019, August 2019, February 2020 and ~~February~~August 2020 for approximately $78,000, $109,000, $112,000 and ~~$112,000,~~$122,000, respectively, in-kind with the issue of additional notes (Interest Notes) to the Purchasers. The Interest Notes have terms identical to the Notes. As

The Company issued 42,672 shares of ~~June 30, 2020,~~its common stock valued at $139,964 to the Note holder in settlement of the accrued interest for the six month period ended February 15, 2021. The Company recorded a loss of $16,898 on this payment, which was recorded in other income in the condensed consolidated statements of operation.

In January and February 2021, a holder of warrants, who was also the holder of the Notes, exercised warrants to purchase 613,791 shares of the Company’s common stock at an exercise price of $2.40 per share for total proceeds of $1,473,098. The proceeds from the exercise of these warrants were used to repay a portion of the principal amount of the Notes.

In March 2021, the Company made a repayment of $1,554,173 in settlement of the outstanding principal amount of the Notes, and ~~Interest Notes could be converted into~~the Note holder’s security interest was terminated. The Company recorded a ~~maximum~~gain of ~~262,375 shares~~$64,757 on the Note settlement, and the gain was recorded in other income in the condensed consolidated statements of common stock at $11.434 per share, excluding the effects of future payments of interest in-kind and a beneficial ownership ceiling of 9.9%. The $3.0 million of outstanding Notes are payable in full in 2023.operations.

PPP Note

On May 7, 2020, the Company entered into a Promissory Note with Wells Fargo Bank, N.A. (the Lender) in an aggregate principal amount of $579,330 (the PPP Note), pursuant to the Paycheck Protection Program (the PPP) under the CARES Act.

The term of the PPP Note is two years. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate of 1.0%, which shall be deferred for the first ~~six~~ten months of the term of the PPP Note. Monthly payments will be due and payable beginning in ~~November 2020~~March 2021 and continue each month thereafter until maturity of the PPP Note. The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, and/or filing suit and obtaining judgment against the Company.

The Company ~~may apply~~applied to the Lender for forgiveness of the PPP Note, under the terms of the PPP. No assurance is provided that the Company will obtain forgiveness of the PPP Note in whole or in part, but the Company ~~intends to use~~believes it has used the proceeds in accordance with the PPP. If the PPP Note is not forgiven, principal payments will be due: ~~$49,000 in 2020, $292,000~~$217,250 in 2021 ~~$238,330~~and $362,080 in 2022.

Note 10. Leases

Effective January 1, 2019, the Company adopted Accounting Standards Update (ASU) No. 2016-02, as amended, using the alternative transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the “effective date method”). Under the effective date method, comparative periods are presented under previous GAAP, Accounting Standards Codification 840, and do not include any retrospective adjustments to reflect the adoption of ASU No. 2016-02. As an accounting policy, theThe Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components. The Company also has elected the package of transition provisions available for existing contracts, which allowed the Company to carryforward its historical assessments of (i) whether contracts are or contain leases, (ii) lease classification and (iii) initial direct costs. The adoption did not result in a cumulative-effect adjustment to the opening balance of accumulated deficit. As a result of the adoption, the Company recorded an operating lease right-of-use asset of $0.4 million and corresponding short-term and long-term liabilities of $0.2 million and $0.2 million, respectively, as of January 1, 2019. The adoption of ASU No. 2016-02 did not have a material impact on the Company’s condensed consolidated statement of operations and comprehensive income or cash flows as of the adoption date.

~~The Company identified only~~ one lease, ~~to be accounted for under ASU No. 2016-02 pertaining to~~which is the lease for its corporate facility ~~which~~that expires in ~~October 2020.~~July 2022, that it accounts for under Accounting Standards Update 2016-02. The right-of-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease payments. The discount rate used to measure the lease asset and liability represents the interest rate on the Notes (8%). Lease expense is recognized on a straight-line basis over the lease term, and operating lease expense was ~~$0.1 million~~approximately $53,000 for the ~~six~~three months ended ~~June 30, 2020.~~ March 31, 2021. The Company ~~has~~does not have an option to extend the lease ~~for an additional 20.5 month period, but, as~~term beyond the ~~renewal is not reasonably certain, it has not included this renewal option in its accounting for the lease.~~current extension.

~~Our future~~Future minimum payments under ~~our~~the facility operating lease at March 31, 2021 are as ~~of June 30, 2020 are listed in the table below~~follows (in thousands):

	Operating			Operating
Year ending December 31,	lease			lease
2020	$	75
2021				$	155
2022					112
Total future lease payments					267
Less: imputed interest		(9	)		(9	)
Present value of lease liabilities	$	66		$	258

Supplemental cash flow information related to the operating lease was as follows (in thousands):

Six months ended

June 30, 2020

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows for lease

$
112

		Three Months Ended
		March 31,
		2021		2020

Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows for lease	$	51	$	56

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this report. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising efforts, the impacts of COVID-19 on our business, ~~all information disclosed under Item 3 of this Part I,~~ and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on March ~~17, 2020~~18, 2021 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” ~~“projects,”~~“projects” or similar expressions are intended to identify forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described under Item 1A of our annual report on Form 10-K for the year ended December 31, ~~2019~~2020 and the risk factors described below under Item 1A of this Form ~~10.~~10-Q. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or events occur in the future.

Company Overview

Our strategy and primary business objective is to be a profitable ~~IP-rich~~intellectual property-rich fabless semiconductor company offering integrated circuits, or ICs, and related software, firmware and intellectual property, or IP, that deliver unparalleled memory bandwidth and access rate performance for high-performance data processing in cloud networking, communications, security appliances, video, test and monitoring, and data center systems. Our solutions deliver time-to-market, performance, power, area and economic benefits for system original equipment manufacturers, or OEMs. Our primary product line is marketed under the Accelerator Engine name and comprises our Bandwidth Engine and Programmable HyperSpeed Engine IC products, which integrate our proprietary, 1T-SRAM high-density embedded memory and a highly-efficient serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance. Our second-generation Bandwidth Engine, or Bandwidth Engine 2, products are expected to be our primary revenue source through at least 2021, and we expect these products to continue to generate significant revenue thereafter. As we are not developing new IC products, from a product development perspective, we continue to leverage our current technologies and core competencies to expand our product offerings without incurring significant additional R&D expenses. ~~Recently, we announced~~We are developing our ~~new~~ Virtual Accelerator Engine, or VAE, product line consisting of software, firmware and IP available for license. This ~~new~~ product line will include multiple function accelerator platform products, which target specific application functions and will use a common software interface to allow performance scalability over multiple hardware environments. These function accelerator platform products are hardware agnostic and operate with or without one of our Accelerator Engine ICs. This software-defined, hardware-accelerated platform architecture utilizes an internally developed graphical memory engine architecture to provide flexible data classification and analysis capability. We believe the technology will generate new opportunities that require less up-front architectural changes by system designers and provide a scalable performance roadmap of options using our Accelerator Engine ICs. Despite our limited new IC product development efforts, we believe our current hardware and software/firmware product portfolio positions us for future growth and profitability.

We incurred net losses of approximately ~~$0.6~~$1.4 million for the ~~six~~three months ended ~~June 30, 2020~~March 31, 2021 and ~~$2.6~~$3.8 million and ~~$11.4~~$2.6 million for the years ended December 31, ~~2019~~2020 and ~~2018,~~2019, respectively, and had an accumulated deficit of approximately ~~$240.9~~$244.0 million as of ~~June 30, 2020.~~March 31, 2021. These and prior year losses have resulted in significant negative cash flows for almost a decade and have necessitated that we raise substantial amounts of additional capital during this period. To date, we have primarily financed our operations through multiple offerings of common stock to investors and affiliates, as well as asset sale transactions and one offering of convertible notes.

We may continue to incur operating losses and will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time.

COVID-19

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on our operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by the U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of our control, and cannot be predicted.

In March 2020, Santa Clara County in California, where we are based, issued a ~~"shelter-in-place"~~”shelter-in-place” order (the Order) that was ~~initially~~ effective through ~~April 7, 2020 and has now been extended.~~the first quarter of 2021. We have been complying with the Order and have minimized business activities at our San Jose headquarters facility (our only facility) since March 2020. We have implemented a teleworking policy for our employees and contractors to reduce on-site activity at our facility. The Order impacted our ability to produce and ship our IC products in the second half of March 2020, as certain of our vendors in the San Francisco Bay Area closed in accordance with the ~~Order (see discussion below, under Results of Operations).~~Order. In April 2020, we resumed shipments of our IC products, as we and our vendors are supporting shipment of components for critical infrastructure, as defined by the federal government; however, our employees are still generally restricted from visiting our customer and vendor sites, ~~in compliance with the Order,~~ and we are unable to conduct certain product testing and development activities.

We remain diligent in continuing to identify and manage risks to our business given the changing uncertainties related to COVID-19. The ultimate impact of the Covid-19 pandemic on our business and results of operations is uncertain and difficult to predict, and we are closely monitoring impacts, especially to customer programs and our supply chain. We expect that the impacts of the COVID-19 pandemic will continue to have a negative impact on our revenues for the remainder of ~~2020,~~2021, although we are not in a position to quantify such impacts. In addition, we have ~~already experienced~~and continue to experience longer lead times for certain components used to manufacture our IC products. While we believe that our operations personnel are currently in a position to meet expected customer demand levels in the coming quarters, we recognize that unpredictable events could create difficulties in the months ahead. We may not be able to address these difficulties in a timely manner, which could negatively impact our business, results of operations, financial condition and cash flows.

The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. WeDuring the quarter ended March 31, 2021, we were ~~recently~~ able to raise additional capital and ~~received a loan under the Paycheck Protection Program~~make full repayment of our convertible notes payable (see discussion below under Liquidity and in ~~Note~~Notes 8 and 9 to the condensed consolidated financial statements included in Part I, Item I of this ~~Report)~~Form 10-Q), however, if we need to raise additional capital to support operations in the future, we may be unable to access the capital markets and additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.

For additional information on risks that could impact our future results, please refer to ~~"Risk Factors"~~“Risk Factors” in Part II, Item 1A. of this ~~Quarterly Report~~quarterly report on Form 10-Q.

Sources of Revenue

Product. Product revenue is generally recognized at the time of shipment to our customers. An estimated allowance may be recorded, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale.

Royalty and other. Our licensing contracts typically provide for royalties based on the licensee’s use of our memory technology in their currently shipping commercial products. We estimate royalty revenue in the period in which the licensee uses the licensed technology. Payments are received in the following period.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the “Notes to Consolidated Financial Statements” in our ~~Annual Report~~annual report on Form 10-K for the year ended December 31, ~~2019.~~2020. As of ~~June 30, 2020,~~March 31, 2021, there have been no material changes to our significant accounting policies and estimates.

Results of Operations

Net ~~Revenue.~~Revenue

	June 30,						Change					March 31,						Change
	2020			2019			2019 to 2020					2021			2020			2020 to 2021
	(dollar amounts in thousands)											(dollar amounts in thousands)
Product -three months ended	$	1,679		$	2,810		$	(1,131	)	(40	)%	$	1,178		$	1,068		$	110	10	%
Percentage of total net revenue		85	%		92	%							88	%		85	%
Product -six months ended	$	2,747		$	6,196		$	(3,449	)	(56	)%
Percentage of total net revenue		85	%		94	%

Product revenue ~~decreased~~increased for the three ~~and six~~ months ended ~~June 30, 2020~~March 31, 2021 compared with the same ~~periods~~period of ~~2019~~2020 primarily due to ~~lower~~higher sales of our Bandwidth Engine ~~products. Approximately $0.7 million of Bandwidth Engine~~2 products, partially offset by decreases in our LineSpeed product ~~shipments were pushed out from the first quarter of 2020 to the second quarter due to COVID-19 shelter-in-place orders.~~sales.

	June 30,						Change				March 31,						Change
	2020			2019			2019 to 2020				2021			2020			2020 to 2021
	(dollar amounts in thousands)										(dollar amounts in thousands)
Royalty and other -three months ended	$	289		$	256		$	33	13	%	$	160		$	192		$	(32	)	(17	)%
Percentage of total net revenue		15	%		8	%						12	%		15	%
Royalty and other -six months ended	$	481		$	390		$	91	23	%
Percentage of total net revenue		15	%		6	%

Royalty and other includes license, royalty and related revenues generated from licensing agreements. The ~~increase~~decrease in royalty and other revenue for the three months ended March 31, 2021 compared with the same period of 2020 was primarily due to ~~higher~~a decrease in royalty ~~revenues in 2020 resulting from higher shipment volumes by licensees whose products incorporate our licensed IP and higher licensing revenue.~~revenue for one licensee.

Cost of Net Revenue and Gross ~~Profit.~~Profit

	June 30,						Change					March 31,						Change
	2020			2019			2019 to 2020					2021			2020			2020 to 2021
	(dollar amounts in thousands)											(dollar amounts in thousands)
Cost of net revenue -three months ended	$	604		$	1,228		$	(624	)	(51	)%	$	495		$	530		$	(35	)	(7	)%
Percentage of total net revenue		31	%		40	%							37	%		42	%
Cost of net revenue -six months ended	$	1,134		$	2,582		$	(1,448	)	(56	)%
Percentage of total net revenue		35	%		39	%

	June 30,						Change					March 31,						Change
	2020			2019			2019 to 2020					2021			2020			2020 to 2021
	(dollar amounts in thousands)											(dollar amounts in thousands)
Gross profit -three months ended	$	1,364		$	1,838		$	(474	)	(26	)%	$	843		$	730		$	113	15	%
Percentage of total net revenue		69	%		60	%							63	%		58	%
Gross profit -six months ended	$	2,094		$	4,004		$	(1,910	)	(48	)%
Percentage of total net revenue		65	%		61	%

Cost of net revenue is primarily comprised of direct and indirect costs related to the sale of our IC products.

Cost of net revenue decreased for the three ~~and six~~ months ended ~~June 30, 2020~~March 31, 2021 when compared with the same period ~~of 2019~~in 2020, primarily due to decreased shipment volumes of our LineSpeed product which was only partially offset by the increase of our Bandwidth Engine products ~~which was partially offset by a $0.1 million write-down of inventory in the second quarter for lead-based Bandwidth Engine 2 products due to the timing of customer transitions to lead-free products.~~that have lower production costs.

Gross profit ~~decreased~~increased for the three ~~and six~~ months ended ~~June 30, 2020,~~March 31, 2021 compared with the same period of ~~2019~~2020 due to the ~~decrease~~increase in gross profit attributable to the ~~reductions~~increases in product revenues. As a percentage of net revenue, gross profit

increased due to higher gross margins on our product sales and higher royalty and other revenue, which generally has no associated cost.

Research and Development

	June 30,						Change					March 31,						Change
	2020			2019			2019 to 2020					2021			2020			2020 to 2021
	(dollar amounts in thousands)											(dollar amounts in thousands)
Research and development -three months ended	$	985		$	981		$	4		0	%	$	1,159		$	961		$	198	21	%
Percentage of total net revenue		50	%		32	%							87	%		76	%
Research and development -six months ended	$	1,946		$	2,134		$	(188	)	(9	)%
Percentage of total net revenue		60	%		32	%

Our research and development expenses include costs related to the development of our IC ~~products~~ and ~~amortization of intangible assets.~~VAE IP products. We expense research and development costs as they are incurred.

The ~~slight~~ increase for the three months ended ~~June 30,~~March 31, 2021 compared with the same period of 2020 was primarily due to increases in ~~expenses for consulting for software development. The decrease for the six months ended June 30, 2020 was primarily~~personnel costs due to ~~decreased prototyping, testing~~new hires and ~~related material~~increases in consulting costs ~~which was partially offset by increased personnel and consulting costs.~~for development of our VAE products. We expect that total research and development expenses will ~~remain relatively consistent~~increase in 2021 compared with 2020 as we incur increased development costs for ~~the remainder of 2020.~~our VAE products.

Selling, General and Administrative

	June 30,						Change				March 31,						Change
	2020			2019			2019 to 2020				2021			2020			2020 to 2021
	(dollar amounts in thousands)										(dollar amounts in thousands)
SG&A -three months ended	$	964		$	932		$	32	3	%	$	1,071		$	1,135		$	(64	)	(6	)%
Percentage of total net revenue		49	%		30	%						80	%		90	%
SG&A -six months ended	$	2,099		$	1,904		$	195	10	%
Percentage of total net revenue		65	%		29	%

Selling, general and administrative, or SG&A, expenses consist primarily of personnel and related overhead costs for sales, marketing, finance, human resources and general management.

The ~~increase~~decrease for the three ~~and six~~ months ended ~~June 30,~~March 31, 2021 compared with the same period of 2020 was primarily due to decreases in professional services and facilities and travel costs, partially offset by increased legal and personnel ~~costs and consulting expenses.~~costs. We expect total SG&A expenses to remain relatively consistent for the remainder of ~~2020.~~2021.

Interest expense

	June 30,						Change				March 31,						Change
	2020			2019			2019 to 2020				2021			2020			2020 to 2021
	(dollar amounts in thousands)										(dollar amounts in thousands)
Interest expense - three months ended	$	56		$	56		$	-	0	%	$	30		$	54		$	(24	)	(44	)%
Percentage of total net revenue		3	%		2	%						2	%		4	%
Interest expense - six months ended	$	111		$	110		$	1	1	%
Percentage of total net revenue		3	%		2	%

Interest expense consisted of interest expense on our senior secured convertible notes (the Notes). ~~To date,~~As of March 31, 2021, we ~~have paid all accumulated interest for~~had repaid the full remaining principal amount of the Notes ~~in-kind through~~and accrued interest. We do not expect to incur interest expense during the ~~issuance~~remainder of ~~identical new senior secured convertible notes.~~2021. See Note 89 to the condensed consolidated financial statements for additional disclosure.

Liquidity and Capital Resources; Changes in Financial Condition

Cash Flows

As of ~~June 30, 2020,~~March 31, 2021, we had cash, cash equivalents and short-term investments of ~~$7.4~~$11.1 million and working capital of ~~$7.7~~$10.9 million. We believe that cash generated from our liquidity sources will be sufficient to meet both our short-term and long-term working capital and capital expenditure needs for the foreseeable future.

Net cash used in operating activities was $1.0 million for the first three months of 2021, which primarily resulted from our net loss of $1.4 million, which was partially offset by $0.3 million in net changes in assets and liabilities and non-cash charges of $0.1 million. The changes in assets and liabilities primarily related to the timing of accounts receivable collections, purchases of inventory and other vendor payables and prepayments.

Net cash used in operating activities was ~~$1.2~~$0.7 million for the first ~~six~~three months of 2020, which primarily resulted from our net loss of ~~$2.0~~$1.4 million, which was partially offset by $0.5 million in net changes in assets and liabilities and non-cash charges of ~~$0.2~~$0.1 million of stock-based compensation, ~~and~~ depreciation and amortization expenses and $0.1 million of accrued interest. The changes in assets and liabilities primarily related to the timing of ~~accounts receivable~~customer collections, and inventory and other vendor payables and prepayments.

Net cash ~~provided by operating~~used in investing activities ~~was $0.4~~of $1.6 million for the ~~first six~~three months ended March 31, 2021 represented purchases of 2019, which primarily resulted from $0.2 in net changes in assets and liabilities and non-cash charges, stock-based compensation of $0.1 million, depreciation and amortization expenses of $0.1 million and accrued interest of $0.1 million, partially offset by net loss of $0.1 million. The changes in assets and liabilities primarily related to the timing of accounts receivable collections and inventory and other vendor payables and prepayments.

short-term investments. Net cash provided by investing activities ~~of $0.3 million~~ for the ~~six~~three months ended ~~June 30,~~March 31, 2020 was mainly due to the proceeds from the maturities of short-term investments of $0.3 million. Net cash used in investing activities of $1.1 million for the six months ended June 30, 2019 was mainly due to the purchase of short-term investments of $1.6 million, which did not affect our liquidity, partially offset by proceeds from the maturities of short-term investments of $0.5 million.

Net cash provided by financing activities of ~~$2.2~~$6.3 million for the ~~six~~three months ended ~~June 30, 2020~~March 31, 2021 primarily consisted of ~~$1.6~~$6.8 million in net proceeds received from the ~~sale of common stock in a~~ registered direct offering of ~~securities~~our common stock completed in ~~April 2020~~February 2021 and ~~$0.6~~$2.5 million of proceeds from ~~an unsecured loan under~~ the ~~Paycheck Protection Program.~~exercise of warrants to purchase shares of common stock at a price of $2.40 per share. We used approximately $3 million of these proceeds to repay in full the outstanding balance of our senior secured convertible notes. There were minimal cash flows used in financing activities during the ~~six~~three months ended ~~June 30, 2019.~~March 31, 2020.

Our future liquidity and capital requirements are expected to vary from quarter-to-quarter, depending on numerous factors, including:

level of revenue;

cost, timing and success of technology development ~~efforts;~~efforts, especially for our VAE products;

inventory levels, timing of product shipments and length of billing and collection cycles;

•

~~fabrication costs, including mask costs, of our ICs, currently under development;~~

variations in manufacturing yields, ~~materials~~material lead time and costs and other manufacturing risks;

profitability of our business;

costs of acquiring other businesses and integrating the acquired operations; and

~~profitability of our business;~~

~~whether interest payments on the Notes are paid in cash or, at our election, in-kind through the issuance of new Notes with identical terms for the accrued interest; and~~

whether the PPP Note is substantially forgiven.

Working Capital

Our primary need for liquidity is to fund working capital requirements of our ~~business,~~businesses, capital expenditures and for general corporate purposes. We expect our cash expenditures to exceed receipts in ~~2020,~~2021, as our revenues will not be sufficient to offset our working capital requirements. During the three months ended March 31, 2021, we received proceeds of $2.5 million from the exercise of common stock warrants, and we used $1.5 million of these proceeds to repay a portion of the principal balance of our senior secured convertible notes. In ~~April 2020,~~February 2021, we completed a registered direct offering of securities that generated net proceeds of approximately ~~$1.6~~$6.8 million. In May 2020, we entered into a Promissory Note with Wells Fargo Bank, N.A. in an aggregate principal amount of approximately $0.6 million (the PPP Note), pursuant to the Paycheck Protection Program (the PPP) under the CARES Act. ~~We intend to apply~~In March 2021 we applied for forgiveness of the PPP Note under the terms of the PPP. No assurance is provided that we will obtain forgiveness of the PPP Note in whole or in part, but we ~~intend to use~~believe we have used the proceeds in accordance with the PPP.

~~If we were to raise~~In the event that additional ~~capital~~financing is required through sales of our equity securities, our stockholders would suffer dilution of their equity ownership, and we may be required to accept other terms that could be significantly detrimental to our existing stockholders and to our business. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness, prohibit us from paying dividends, repurchasing our stock or making investments, and force us to maintain specified liquidity or other ratios, any of which could be significantly detrimental

to our business, operating results and financial condition. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:

~~repay the Notes and the PPP Note when they are due;~~

develop or enhance our products;

expand our product development and sales and marketing organizations;

acquire complementary technologies, products or businesses;

expand operations;

hire, train and retain employees; or

respond to competitive pressures or unanticipated working capital requirements.

Our failure to do any of these things could seriously harm our ability to execute our business strategy and may force us to curtail our existing operations or research and development plans.

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements or obligations that are reasonably likely to have a material current or future effect on our financial condition, results of operations, liquidity or capital resources.

ITEM 4. Controls and Procedures

Disclosure Controls and Procedures. Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that, as of ~~June 30, 2020,~~March 31, 2021, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting. During the ~~six~~three months ended ~~June 30, 2020,~~March 31, 2021, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. Legal Proceedings

The discussion of legal matters in Note 4 of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report under the heading “Legal Matters” is incorporated by reference in response to this Part II, Item 1.

ITEM 1A. Risk Factors

We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. Except as set forth below, there have been no material changes with respect to the risk factors disclosed under Item 1A of our annual report on Form 10-K for the year ended December 31, ~~2019,~~2020, which we filed with the SEC on March ~~17, 2020.~~18, 2021.

The full effects of COVID-19 and other potential future public health crises, epidemics, pandemics or similar events are uncertain and could have a material and adverse effect on our business, financial condition, operating results and cash flows.

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the world economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The extent of the impact on our operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of our control and cannot be predicted.

In accordance with applicable U.S. governmental ordinances generally exempting essential businesses and/or critical infrastructure workforces from mandated closures and orders to “shelter-in-place,” we are operating in support of essential products and services, subject to limitations and requirements in applicable state and county orders. We have been complying with county and state orders and have implemented a work-from-home policy for our employees and contractors and significantly minimized the number of employees who visit our office. However, a facility closure, work slowdowns or temporary stoppage at one of our production vendors could occur, which could have a longer-term impact and could delay our deliveries to customers and ability to conduct business. For example, the “shelter-in-place” orders impacted our ability to produce and ship our IC products in the second half of March, as certain of our vendors in the San Francisco Bay Area closed in accordance with governmental orders.

If significant portions of our workforce are unable to work effectively, including because of illness, quarantines, absenteeism, government actions, facility closures, travel restrictions or other restrictions in connection with the COVID-19 pandemic, our operations will be negatively impacted. We may be unable to market and sell our products, and our costs may increase as a result of the COVID-19 outbreak. The impacts could worsen if there is an extended duration of any COVID-19 outbreak or a resurgence of COVID-19 infection in affected regions after they have begun to experience improvement.

We rely on other companies to provide raw materials and to perform manufacturing and testing of our products. An extended period of global supply chain disruption, including extended lead times to purchase materials or procure testing services caused by the response to COVID-19 could impact our ability to ship our products. For example, we have already experienced longer lead times for certain components used to manufacture our IC products. If we are not able to implement alternatives or other mitigations, product deliveries would be adversely impacted and negatively impact our business, financial condition, operating results and cash flows.

As a result of COVID-19, we could see delays in new customer product programs and reduced customer demand for our products, which would adversely affect our revenues, financial performance and cash flows, and could result in asset impairments. Delays in transaction processing, including payment processing, by our customers, many of whom are teleworking, could also affect our revenues and cash flows, and current limitations on travel to customers could impact orders and business prospects. Limitations on government operations can also impact regulatory approvals that may be necessary for us to operate our business.

The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. We were recently able to raise additional capital, however, if we need to raise additional capital to support operations in the future, we may be unable to access the capital markets and additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a)

Unregistered sales of equity securities:

On February 1, 2021, the Company issued 42,672 shares of its common stock valued at $139,964 to the holder of the Senior Secured Convertible Notes due August 15, 2023 in settlement of the accrued interest for the six month period ended February 15, 2021. Such shares were issued in a private placement transaction that was exempt from the registration requirements under the Securities Act pursuant to Section 4(a)(2) of the Securities Act.

~~ITEM~~ ITEM 6. Exhibits

(a)	Exhibits

	~~10.1~~	~~Paycheck Protection Program Promissory Note and Agreement dated May 3, 2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 13, 2020)~~
	~~10.2~~10.22(1)	Form of Securities Purchase Agreement ~~(incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April~~dated February 17, ~~2020)~~2021
	~~31.1~~10.23*	First Amendment to Executive Severance and Change-In-Control Policy dated April 28, 2021
	31.1*	Rule 13a-14 certification
	~~31.2~~31.2*	Rule 13a-14 certification
	32.1**	Section 1350 certification
	~~101~~101*	The following financial information from MoSys, Inc.’s ~~Quarterly Report~~quarterly report on Form 10-Q for the period ended ~~June 30, 2020,~~March 31, 2021, filed with the SEC on ~~August 12, 2020,~~May 13, 2021, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three ~~and six~~ months ended ~~June 30,~~March 31, 2021 and 2020, ~~and 2019,~~ (ii) the Condensed Consolidated Balance Sheets as of ~~June 30, 2020~~March 31, 2021 and December 31, ~~2019,~~2020, (iii) the Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three ~~and six~~ months ended ~~June 30,~~March 31, 2021 and 2020, ~~and 2019,~~ (iv) the Condensed Consolidated Statements of Cash Flows for the ~~six~~three months ended ~~June 30,~~March 31, 2021 and 2020, ~~and 2019,~~ and (v) Notes to Condensed Consolidated Financial Statements.

	(1)	Incorporated by reference to Exhibit 10.1 to Form 8-K filed by the Company on February 17, 2021 (Commission File No. 000-32929

*Filed herewith.

* The material contained in Exhibit 32.1 is not deemed “filed” with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language contained in such filing, except to the extent that the registrant specifically incorporates it by reference*Furnished herewith.

~~Signatures~~Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Dated: ~~August 12, 2020~~May 13, 2021		MOSYS, INC.

	By:	/s/ Daniel Lewis
		Daniel Lewis
		President and Chief Executive Officer (Principal Executive Officer)

	By:	/s/ James W. Sullivan
		James W. Sullivan
		Vice President of Finance and Chief Financial Officer
		(Principal Financial and Accounting Officer)

2724

	June 30, 2020
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
Cash and cash equivalents	$	7,375	$	—	$	—	$	7,375

	December 31, 2019
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
Cash and cash equivalents	$	6,053	$	—	$	—	$	6,053
Short-term investments		300		—		—		300
	$	6,353	$	—	$	—	$	6,353